Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.37 |
| ▸ | PPIA | P62937 | 1/20 | 0.36 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.33 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 3/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136153 | 0.80 | MAOA (0.31) | — | |
| SCHEMBL24818239 | 0.80 | PPIA (0.39) | DRD2PPIANPFFR1NPFFR2CACNA1H | |
| SCHEMBL23692608 | 0.80 | PPIA (0.39) | DRD2PPIANPFFR1NPFFR2CACNA1H | |
| SCHEMBL31491350 | 0.77 | SMN1; SMN2 (0.43) | DRD2PPIACTSLCTSBCTSK | |
| SCHEMBL24815894 | 0.75 | KMT2A (0.35) | DRD2PPIACACNA1HCTSLCTSK | |
| SCHEMBL2868997 | 0.74 | DRD2 (0.34) | DRD2CTSLCTSBCTSKCTSD | |
| SCHEMBL2870818 | 0.74 | DRD2 (0.53) | DRD2CACNA1H | |
| SCHEMBL20069700 | 0.71 | CACNA1H (0.37) | DRD2PPIANPFFR1NPFFR2CACNA1H | |
| SCHEMBL56916 | 0.70 | TDP1 (0.41) | DRD2PPIACTSLCTSKP2RX7 | |
| SCHEMBL14173595 | 0.70 | KMT2A (0.38) | PPIACTSLCTSKP2RX7APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | DRD2 1250/4885PPIA 3704/4885NPFFR1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.